Piramal Pharma Ltd (PPLPHARMA) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management upgraded full-year FY27 revenue growth guidance to 19-20% with 'meaningfully higher' profitability growth, citing strong H1 momentum and order visibility.
- The multi-geography CDMO strategy is paying off, with North American sites seeing improved demand, order flow, and profitability, validating the on-shore/off-shore model.
- The high effective tax rate will persist short-term, with benefits from utilizing $580 million in overseas tax losses expected to start over the next 2-3 years.
Performance Overview
- Delivered strong performance with broad-based contributions from all three business segments: CDMO, Complex Hospital Generics, and Consumer Healthcare.
- Reported significant year-on-year growth in both revenue (28%) and EBITDA (72%) for the quarter, highlighting improved profitability.
- EBITDA margins expanded by over 350 basis points, driven by better capacity utilization, operating leverage, and disciplined cost management.
- Maintained a strong focus on quality and compliance, successfully completing 12 regulatory inspections and 110 customer audits in H1 FY27.
- Upgraded full-year FY27 guidance, now expecting revenue growth of 19-20% with meaningfully higher growth in profitability.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.